Coverage
Filings
Genmab A/S announced encouraging results from its Phase 1/2 RAINFOL-01 trial for rinatabart sesutecan (Rina-S), an investigational antibody-drug conjugate (ADC), in heavily pretreated patients with advanced endometrial cancer.
| 14 Dec 2022 |
| Capital Increase in Genmab as a Result of Employee Warrant Exercise | 13 Dec 2022 |
| Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons | 13 Dec 2022 |
| Genmab to Hold 2022 R&D Update and ASH Data Review Meeting | 12 Dec 2022 |
| Genmab Showcases Data From Robust Development Program Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients Across a Broad Range of B-Cell Lymphomas at the 64th Annual ASH Meeting | 11 Dec 2022 |
| Genmab A/S has published its Articles of Association | 29 Nov 2022 |